ACLX - Arcellx Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.123B

Cash

506.5M

Avg Qtr Burn

N/A

Short % of Float

18.67%

Insider Ownership

7.39%

Institutional Own.

93.17%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CART-ddBCMA Details Multiple myeloma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACLX-001 (ARC-SparX program) Details Multiple myeloma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACLX-002 (ARC-SparX program) Details Myelodysplastic syndrome, Acute myeloid leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.